Faeth Therapeutics, Inc. (FTH) Income Statement
FTH 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsFTH revenue and net income
FTH growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
FTH quarterly EPS vs estimates
Faeth Therapeutics beat the analyst EPS estimate in 5 of the last 7 quarters. Next report: November 13, 2026 (estimate $-0.66).
FTH income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $551,000 | $571,000 | $1.8M | $685,000 | $209,000 | $73,000 | $44,000 |
| Gross profit | — | −$551,000 | −$571,000 | −$1.8M | −$685,000 | −$209,000 | −$73,000 | −$44,000 |
| Research & development | $11.0M | $18.6M | $18.3M | $29.6M | $21.7M | $11.9M | $8.3M | $8.2M |
| Sales, general & admin | $11.3M | $13.0M | $18.8M | $19.8M | — | $7.5M | — | $4.5M |
| Total operating expenses | $22.3M | $31.1M | $36.5M | $47.3M | $36.8M | $19.2M | $12.4M | $12.7M |
| Operating income | −$22.3M | −$31.7M | −$37.1M | −$49.1M | −$37.5M | −$19.5M | −$12.4M | −$12.7M |
| Interest income | $1.2M | $2.5M | $3.6M | $1.8M | — | — | — | — |
| Interest expense | $32,000 | $90,000 | $144,000 | $219,000 | $670,000 | $1.7M | $2.3M | $327,000 |
| Income before taxes | −$21.1M | −$30.2M | −$34.1M | −$48.6M | −$36.8M | −$20.1M | −$16.7M | −$13.0M |
| Net income | −$21.1M | −$30.2M | −$34.1M | −$48.6M | −$36.8M | −$20.1M | −$16.7M | −$13.0M |
| EBITDA | −$20.9M | −$28.7M | −$35.6M | −$47.0M | −$35.4M | −$18.2M | −$14.4M | −$12.7M |
| EPS (diluted) | −$16.72 | −$23.24 | −$24.30 | −$31.65 | −$26.60 | −$3.35 | −$11.42 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $133.0M | — | −$4.9M | — | — | $139,000 | $140,000 | $135,000 | $137,000 | $135,000 | $455,000 |
| Gross profit | — | −$133.0M | — | $4.9M | — | — | −$139,000 | −$140,000 | −$135,000 | −$137,000 | −$135,000 | −$455,000 |
| Research & development | $9.2M | $18.0M | $2.2M | $2.5M | $2.5M | $3.7M | $4.5M | $4.6M | $4.6M | $4.9M | $4.5M | $3.8M |
| Sales, general & admin | $9.2M | $19.7M | $2.8M | $2.3M | $2.7M | $3.5M | — | — | — | $3.8M | — | — |
| Total operating expenses | $18.4M | $37.7M | $5.0M | $4.9M | $5.2M | $7.3M | $7.2M | $7.7M | $7.7M | $8.6M | $8.0M | $7.3M |
| Operating income | −$18.4M | −$170.6M | −$5.0M | −$4.9M | −$5.2M | −$7.3M | −$7.3M | −$7.8M | −$7.8M | −$8.7M | −$8.1M | −$7.7M |
| Interest income | $2.3M | $392,000 | $223,000 | $289,000 | $321,000 | $392,000 | — | — | — | — | — | — |
| Interest expense | — | — | $3,000 | $6,000 | $10,000 | $13,000 | $17,000 | $21,000 | $24,000 | $28,000 | $31,000 | $33,000 |
| Income before taxes | −$16.0M | −$170.2M | −$4.7M | −$4.6M | −$4.9M | −$6.9M | −$7.8M | −$7.3M | −$7.1M | −$8.0M | −$7.4M | −$7.1M |
| Net income | −$16.0M | −$170.2M | −$4.7M | −$4.6M | −$4.9M | −$6.9M | −$7.8M | −$7.3M | −$7.1M | −$8.0M | −$7.4M | −$7.1M |
| EBITDA | −$16.0M | −$170.2M | −$4.7M | −$4.5M | −$4.9M | −$6.8M | −$7.6M | −$7.1M | −$7.0M | −$7.8M | −$7.2M | −$6.6M |
| EPS (diluted) | −$2.84 | −$131.45 | −$3.74 | −$3.62 | −$3.91 | −$5.45 | −$5.46 | −$5.80 | −$5.60 | −$6.38 | −$6.00 | −$5.58 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in FTH's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
FTH financial results
Faeth Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $21.1 million. Diluted earnings per share came to −$16.72.
See the FTH stock overview for the latest quote and news, or the FTH chart for price history and technical indicators.
FTH income statement FAQ
Does Faeth Therapeutics have revenue?
Faeth Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Faeth Therapeutics profitable?
No. Faeth Therapeutics reported a net loss of $21.1 million in fiscal 2025.
How much does Faeth Therapeutics spend on research and development?
Faeth Therapeutics spent $11.0 million on research and development in fiscal 2025.
What are Faeth Therapeutics's earnings per share?
Faeth Therapeutics earned $-16.72 per diluted share in fiscal 2025, compared with $-23.24 a year earlier.
When will Faeth Therapeutics report its next earnings?
Faeth Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Faeth Therapeutics's fiscal year end?
Faeth Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.